Prescient Therapeutics Limited (ASX:PTX)
Share Pricing & News Healthcare

AUD 0.14

-0.01 (6.667%)
(As on 2022-12-08 20:57:08 AEDT)
Previous Close Open Close*
0.15 0.15 0.14
Market Cap Dividend Yield (Annualized)
AUD 100.773M 0.00%

Day Range
0.14L 0.15 H
0.115L 0.255 H

Chart Price & Information

Last Trade 0.14
Change% -6.6667
52 W H/L 0.255/0.115
EBITDA -5.109M
NPAT After Abnormal Items -5.117M
Equity 16.762M
ROE% -30.53%
Total Liabilities 856,013
Total Revenue 1.889M
Cash and Cash Equivalents 12.264M

Stock Information

Share price 0.14
Market Cap 100.773M
Price/Gross Cash Flow -28.12
Dividend Yield Excluding Special 0.00%
Ending Shares 654.323M
52-Week Range 0.255-0.115
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.02
P/E ratio 0.000
Sector P/E --
EPS -0.79
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.01
Net Gearing -73.16%
Sales Per Share 0.00
Book Value Per Share 0.03

Similar Companies

Related Articles

About Company

ASX-listed clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) is focused on the development of revolutionary personalised therapies for challenging cancers having unmet medical need. Prescient’s key programs are universal CAR-T and targeted therapies. Both approaches seek to improve patient outcomes and develop new tools for clinicians to combat cancer.

Notably, Prescient Therapeutics is backed by a leading team of global cancer specialists who hold extensive experience in advancing new cancer therapies.

Prescient has a comprehensive product pipeline of personalised cancer treatments for several different cancers:

Source: PTX Website

CAR-T therapies include OmniCAR and Cell Therapy Enhancement Programs

OmniCAR program: Prescient’s universal CAR-T platform, OmniCAR, employs technology that is licensed from the University of Pennsylvania and Oxford University.

PTX’s pioneering OmniCAR program will allow unprecedented control and flexibility over the current generation CAR-T methods.

Interestingly, Prescient has announced three next-generation OmniCAR programs for AML, Her2+ solid tumours and glioblastoma multiforme (GBM). PTX has also entered into a new research agreement with Peter MacCallum Cancer Centre to advance its CAR-T programs.

Cell Therapy Enhancements (CTE): Prescient’s CTE programs are progressing well with initial promising findings. Two CTE programs are underway with Peter MacCallum and Carina Biotech, respectively.

Targeted Therapies - PTX-100 and PTX-200  

PTX-100 is a first in class RhoA inhibitor and can block GGT-1 (geranylgeranyl transferase-1), a crucial cancer growth enzyme.

  • Currently, the compound is in a PK/PD basket study to treat hematological and solid cancers, focusing on malignancies with Ras and RhoA mutations.
  • In an earlier Phase 1 trial for advanced solid tumours, PTX-100 achieved stable disease and was well tolerated.

PTX-200, a novel PH domain inhibitor, blocks Akt pathway. Akt plays a vital role in the development of numerous malignancies, including breast and ovarian cancer and leukemia.  

  • PTX-200 has a unique mechanism of particularly inhibiting the Akt pathway in a comparatively safe manner, unlike other drugs targeting Akt inhibition.
  • PTX-200 has previously reported promising data in Phase 2a study for HER2-negative breast cancer and Phase 1b trial in ovarian cancer (recurrent or persistent platinum-resistant).
  • Currently, Prescient is assessing PTX-200 in relapsed and refractory Acute Myeloid Leukemia.

Corporate Information

Level 4, 100 Albert Road, SOUTH MELBOURNE, VIC, AUSTRALIA, 3205

Phone:(03) 9692 7222



Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-08-22 2023
Report (Prelim) 2023-08-22 2023
Report (Interim) 2023-02-24 2023